Molecular Pathology of MYCN Amplification

MYCN amplification occurs in about 20 % of NB and is a well-established clinical marker of aggressive disease used for patient risk stratification. Amplification leads to high levels of MYCN expression in most cases and is believed to directly contribute to tumor biology. Although MYCN is a transcriptional regulator, few specific in vivo targets have been identified and the mechanisms by which MYCN contributes to aggressive tumor biology are not known (Seeger et al.

NB samples

0 0

Post a comment